Wendy Atkin obituary
Epidemiologist whose research led to a breakthrough in bowel cancer screening programmes worldwide“Breakthrough” is an overused word when applied to medical advances. But in the case of the2010 trial of a new screening test for bowel cancer led by Wendy Atkin, professor of gastrointestinal epidemiology atImperial College London, who has died of acute myeloid leukaemia aged 71, it is fully deserved. Its impact will be felt by millions. The trial was the first in the world to show that bowel cancer – the second biggest cancer killer in the UK – could be prevented with a simple, five-minute test.The examination – where a sigmoidoscope (a camera mounted on a thin, flexible tube) is inserted into the rectum to detect polyps, which are then ablated (burnt) or snipped off – is now being offered to all 55- to 60-year-olds in England after a follow-up study showed it reduced deaths from bowel cancer by 43% f or as long as 17 years after screening, making it the most effective of all cancer screening tests. In the lower bowel, the test prevented half of potential cancers from developing in that area.Continue reading...
(Wiley) Survivors of childhood brain tumors who received radiotherapy and were very young at the time of diagnosis may experience cognitive and socioeconomic burdens decades after treatment, according to a study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. Interventions such as cognitive therapies and educational and occupational services may be needed to mitigate such long-term effects.
British Journal of Cancer, Published online: 24 June 2019; doi:10.1038/s41416-019-0495-5The role of mouse tumour models in the discovery and development of anticancer drugs
British Journal of Cancer, Published online: 24 June 2019; doi:10.1038/s41416-019-0500-zObesity, abdominal obesity and subsequent risk of kidney cancer: a cohort study of 23.3 million East Asians
British Journal of Cancer, Published online: 24 June 2019; doi:10.1038/s41416-019-0504-8RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
ConclusionOCWAA is uniquely positioned to study the epidemiology of EOC in AA women compared with white women to address disparities. Studies of EOC have been underpowered to address factors that may explain AA-white differences in the incidence and survival. OCWAA promises to provide novel insight into disparities in ovarian cancer.
Conclusions: p65BTK is frequently expressed in CRC and, if highly expressed, is an unfavourable prognostic factor. However, further confirmation is needed and its potential targeting needs to be studied.